Lung Cancer | Specialty

Tepotinib Displays Durable Clinical Benefit in METex14-Altered NSCLC

May 31st 2020

The oral, highly selective MET inhibitor tepotinib demonstrated durable clinical activity in patients with locally advanced or metastatic non–small cell lung cancer who harbor a MET exon 14 skipping mutation identified through liquid or tissue biopsy.

Tislelizumab Frontline Combos Extend PFS in Squamous NSCLC

May 31st 2020

Combining the anti–PD-1 agent tislelizumab with chemotherapy improved progression-free survival compared with chemotherapy alone as a frontline treatment in Chinese patients with advanced squamous non–small cell lung cancer.

Frontline Durvalumab Maintains OS Benefit in Extensive-Stage Small Cell Lung Cancer

May 31st 2020

The addition of durvalumab to standard chemotherapy continued to demonstrate an improvement in overall survival for patients with treatment-naïve extensive-stage small cell lung cancer.

AMG 510 Shows Clinical Activity in Advanced KRAS G12C-Mutant Solid Tumors

May 30th 2020

AMG 510, a novel KRAS G12C inhibitor, demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors other than non–small cell lung cancer and colorectal cancer.

FDA Approves Ramucirumab Plus Erlotinib for Frontline EGFR+ NSCLC

May 30th 2020

The FDA has approved the combination of ramucirumab and erlotinib as a frontline treatment for patients with metastatic non–small cell lung cancer whose tumors harbor EGFR mutations.

Dr. Santos on the FDA Approval of Ramucirumab/Erlotinib in EGFR-Mutant NSCLC

May 30th 2020

Edgardo S. Santos, MD, FACP, FCCP, discusses the FDA approval of the combination of ramucirumab and erlotinib for the frontline treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors harbor EGFR Ex19del or Ex21 substitution mutations.

Frontline Nivolumab/Ipilimumab Combo with Limited Chemo Improves OS in NSCLC

May 30th 2020

Results from the CheckMate 9LA suggested that frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer should be considered a new option for this population.

Pembrolizumab Added to Etoposide Plus Platinum Chemotherapy Provides Modest Survival Benefit in ES-SCLC

May 29th 2020

Modest survival benefits were observed in patients with extensive-stage small cell lung cancer who received the combination of pembrolizumab and etoposide plus platinum compared with patients who received EP and placebo.

Nivolumab/Ipilimumab Combo Induces Durable Responses in Advanced NSCLC

May 29th 2020

Following at least 3 years of follow-up, patients with advanced non-small cell lung cancer and tumor PD-L1 expression ≥ 1% or < 1% experienced durable and long-term efficacy benefits from frontline treatment with nivolumab plus ipilimumab, compared with chemotherapy.

Trastuzumab Deruxtecan Induces Durable Responses in HER2-Mutant NSCLC

May 29th 2020

Fam-trastuzumab deruxtecan-nxki demonstrated favorable clinical activity with a high objective response rate and durable responses in patients with HER2-mutated non–small cell lung cancer.

Dr. Johnson on the Results of the CITYSCAPE Trial in PD-L1+ NSCLC

May 29th 2020

Melissa L. Johnson, MD, discusses the results of the phase 2 CITYSCAPE trial in PD-L1–positive non–small cell lung cancer (NSCLC).

Novel Anti-TIGIT Agent Tiragolumab Plus Atezolizumab Impresses in NSCLC

May 29th 2020

Patients with chemotherapy-naïve, locally advanced or metastatic non–small cell lung cancer who were treated in the phase 2 CITYSCAPE trial with tiragolumab, an inhibitor of the immunomodulatory receptor TIGIT, plus and anti–PD-L1 agent demonstrated better efficacy versus single-agent checkpoint inhibitor therapy alone.

Adjuvant Osimertinib Significantly Improves DFS in Early-Stage EGFR+ NSCLC

May 29th 2020

Adjuvant treatment with osimertinib demonstrated an 83% reduction in the risk of disease recurrence or death in patients with stage II to IIIA EGFR-mutant non–small cell lung cancer.

Atezolizumab Combo Approved in UK for Small Cell Lung Cancer

May 28th 2020

Atezolizumab in combination with carboplatin and etoposide has been approved in the UK for the frontline treatment of patients with extensive-stage small cell lung cancer.

FDA Approves Nivolumab/Ipilimumab Plus Chemo for Frontline NSCLC

May 27th 2020

The FDA has approved nivolumab combined with ipilimumab and chemotherapy for use as a frontline treatment for patients with metastatic or recurrent non–small cell lung cancer.

Dr. Thawani on AEs With Radiation Versus COVID-19 Symptoms in Lung Cancer

May 23rd 2020

Nitika Thawani, MD, discusses identifying the difference between adverse events that are associated with radiation versus COVID-19 symptoms in lung cancer.

Dr. Dimou on Managing Disease Progression in NSCLC

May 22nd 2020

Anastasios (Tassos) Dimou, MD, shares advice from managing patients with non–small cell lung cancer who experience disease progression following therapy.

Future of NTRK Fusions

May 21st 2020

Challenges for TRK Fusion–Targeting Agents

May 21st 2020

Acquired Resistance in TRK Fusion-Positive Cancers

May 21st 2020